View this month's CBD Newsletter to learn more!
Buyer beware and validate scientific claims
The New York Times debunked research cited in Wana Brands’ marketing materials for its Fit gummies. Marketing materials said 100 out of 100 of participants who took the brand’s cannabinoid-packed weight loss gummies lost weight in a trial performed under the guidance of the Mayo Clinic. The Mayo Clinic, however, has no record of the research. Read on at The New York Times.
|
|
|
|
Learn about the FDA DAP
FDA Cannabis-Derived Products Data Acceleration Plan (DAP) is a portfolio of pilot initiatives and partnerships focused on advancing data-driven safety signal detection and building advanced technology capabilities. The DAP’s primary goal is to leverage novel data sources and advanced data analytics to identify current and emerging safety vulnerabilities in the Cannabis-derived products (CDP) market. |
|
|
|
|
